The effects of augmented visual feedback during balance training in Parkinson's disease

Improving Mobility and balance in PArkinson's disease through circuit Class Training: Effects on clinical outcomes, posturography and brain connectivity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN47046299

Enrollment

Registered

2013-07-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Movement disorders

Interventions

Patients are allocated to either the experimental or control group. The intervention will contain ten treatment sessions of 60 minutes each over a period of five weeks. In order to efficiently organi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A diagnosis of idiopathic Parkinson's disease (PD), mild to moderate stage (i.e. Hoehn & Yahr stages II and III) 2. Able to participate in either of the training programs 3. Written and verbal informed consent. 4. Male and female subjects of all ages

Exclusion criteria

Exclusion criteria: 1. The presence of neurological, orthopedic, or cardiopulmonary problems that can impair participation 2. Insufficient cognitive function (Mini Mental State Examination, MMSE < 24) 3. An unstable medication regime 4. Any condition that renders the patient unable to understand or adhere to the protocol such as cognitive, visual, and/or language problems.

Design outcomes

Primary

Measure	Time frame
Functional Reach Test measured at baseline, at six weeks, and at 12 weeks.	—

Secondary

Measure	Time frame
Clinical outcome measures 1. Berg Balance Scale 2. Falls Efficacy Scale 3. 10 meter Walk Test 4. Parkinson's Disease Questionnaire 5. Hospital Anxiety and Depression scale 6. Multidimensional Fatigue Inventory Posturography during quiet stance 1. Variability: COP standard deviation 1.1. anterioposterior direction (SDCOP,x) 1.2. mediolateral direction (SDCOP,y) 2. Local stability: maximum Lyapunov exponent 3. Regularity: sample entropy 4. Number of active control variables: correlation dimension 5. Correlations: scaling exponent EEG (plus MRI) 1. Source of activity / regions of interest (dipole fits / beamformers) 2. Spectral power changes (in particular motor-related beta- and alpha-power) 3. Intra- / inter-hemispheric synchronization (phase coherence, synchronization likelihood) 4. Topological changes of overall functional connectivity (sensor-based network estimates) All above outcomes measured at baseline, at six weeks, and at 12 weeks.	—

Measure

Time frame

Clinical outcome measures 1. Berg Balance Scale 2. Falls Efficacy Scale 3. 10 meter Walk Test 4. Parkinson's Disease Questionnaire 5. Hospital Anxiety and Depression scale 6. Multidimensional Fatigue Inventory Posturography during quiet stance 1. Variability: COP standard deviation 1.1. anterioposterior direction (SDCOP,x) 1.2. mediolateral direction (SDCOP,y) 2. Local stability: maximum Lyapunov exponent 3. Regularity: sample entropy 4. Number of active control variables: correlation dimension 5. Correlations: scaling exponent EEG (plus MRI) 1. Source of activity / regions of interest (dipole fits / beamformers) 2. Spectral power changes (in particular motor-related beta- and alpha-power) 3. Intra- / inter-hemispheric synchronization (phase coherence, synchronization likelihood) 4. Topological changes of overall functional connectivity (sensor-based network estimates) All above outcomes measured at baseline, at six weeks, and at 12 weeks.

—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 19, 2026